170 related articles for article (PubMed ID: 26720150)
1. New Strains Intended for the Production of Inactivated Polio Vaccine at Low-Containment After Eradication.
Knowlson S; Burlison J; Giles E; Fox H; Macadam AJ; Minor PD
PLoS Pathog; 2015 Dec; 11(12):e1005316. PubMed ID: 26720150
[TBL] [Abstract][Full Text] [Related]
2. Development of inactivated poliovirus vaccine from Sabin strains: A progress report.
Okayasu H; Sein C; Hamidi A; Bakker WA; Sutter RW
Biologicals; 2016 Nov; 44(6):581-587. PubMed ID: 27720268
[TBL] [Abstract][Full Text] [Related]
3. An Introduction to Poliovirus: Pathogenesis, Vaccination, and the Endgame for Global Eradication.
Minor PD
Methods Mol Biol; 2016; 1387():1-10. PubMed ID: 26983727
[TBL] [Abstract][Full Text] [Related]
4. Vaccine-derived poliovirus (VDPV): Impact on poliomyelitis eradication.
Minor P
Vaccine; 2009 May; 27(20):2649-52. PubMed ID: 19428874
[TBL] [Abstract][Full Text] [Related]
5. Rational design of genetically stable, live-attenuated poliovirus vaccines of all three serotypes: relevance to poliomyelitis eradication.
Macadam AJ; Ferguson G; Stone DM; Meredith J; Knowlson S; Auda G; Almond JW; Minor PD
J Virol; 2006 Sep; 80(17):8653-63. PubMed ID: 16912313
[TBL] [Abstract][Full Text] [Related]
6. Risks associated with the use of live-attenuated vaccine poliovirus strains and the strategies for control and eradication of paralytic poliomyelitis.
Pliaka V; Kyriakopoulou Z; Markoulatos P
Expert Rev Vaccines; 2012 May; 11(5):609-28. PubMed ID: 22827246
[TBL] [Abstract][Full Text] [Related]
7. Twenty-Eight Years of Poliovirus Replication in an Immunodeficient Individual: Impact on the Global Polio Eradication Initiative.
Dunn G; Klapsa D; Wilton T; Stone L; Minor PD; Martin J
PLoS Pathog; 2015 Aug; 11(8):e1005114. PubMed ID: 26313548
[TBL] [Abstract][Full Text] [Related]
8. Genetically Thermo-Stabilised, Immunogenic Poliovirus Empty Capsids; a Strategy for Non-replicating Vaccines.
Fox H; Knowlson S; Minor PD; Macadam AJ
PLoS Pathog; 2017 Jan; 13(1):e1006117. PubMed ID: 28103317
[TBL] [Abstract][Full Text] [Related]
9. Eradicating polio: how the world's pediatricians can help stop this crippling illness forever.
Orenstein WA;
Pediatrics; 2015 Jan; 135(1):196-202. PubMed ID: 25548328
[TBL] [Abstract][Full Text] [Related]
10. The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study.
Van Damme P; De Coster I; Bandyopadhyay AS; Revets H; Withanage K; De Smedt P; Suykens L; Oberste MS; Weldon WC; Costa-Clemens SA; Clemens R; Modlin J; Weiner AJ; Macadam AJ; Andino R; Kew OM; Konopka-Anstadt JL; Burns CC; Konz J; Wahid R; Gast C
Lancet; 2019 Jul; 394(10193):148-158. PubMed ID: 31174831
[TBL] [Abstract][Full Text] [Related]
11. Development and introduction of inactivated poliovirus vaccines derived from Sabin strains in Japan.
Shimizu H
Vaccine; 2016 Apr; 34(16):1975-85. PubMed ID: 25448090
[TBL] [Abstract][Full Text] [Related]
12. [History of development of the live poliomyelitis vaccine from Sabin attenuated strains in 1959 and idea of poliomyelitis eradication].
Lashkevich VA
Vopr Virusol; 2013; 58(1):4-10. PubMed ID: 23785754
[TBL] [Abstract][Full Text] [Related]
13. Newcastle Disease Virus-Based Vectored Vaccine against Poliomyelitis.
Viktorova EG; Khattar SK; Kouiavskaia D; Laassri M; Zagorodnyaya T; Dragunsky E; Samal S; Chumakov K; Belov GA
J Virol; 2018 Sep; 92(17):. PubMed ID: 29925653
[TBL] [Abstract][Full Text] [Related]
14. Brunenders: a partially attenuated historic poliovirus type I vaccine strain.
Sanders BP; Liu Y; Brandjes A; van Hoek V; de Los Rios Oakes I; Lewis J; Wimmer E; Custers JHHV; Schuitemaker H; Cello J; Edo-Matas D
J Gen Virol; 2015 Sep; 96(9):2614-2622. PubMed ID: 26018960
[TBL] [Abstract][Full Text] [Related]
15. A novel gamma radiation-inactivated sabin-based polio vaccine.
Tobin GJ; Tobin JK; Gaidamakova EK; Wiggins TJ; Bushnell RV; Lee WM; Matrosova VY; Dollery SJ; Meeks HN; Kouiavskaia D; Chumakov K; Daly MJ
PLoS One; 2020; 15(1):e0228006. PubMed ID: 31999745
[TBL] [Abstract][Full Text] [Related]
16. Risks of reintroduction of polio after eradication: the vaccine origin of an outbreak of type 3 poliomyelitis.
Martin J; Ferguson GL; Wood DJ; Minor PD
Dev Biol (Basel); 2001; 105():83-92. PubMed ID: 11763341
[TBL] [Abstract][Full Text] [Related]
17. Nucleotide variation in Sabin type 3 poliovirus from an Albanian infant with agammaglobulinemia and vaccine associated poliomyelitis.
Foiadelli T; Savasta S; Battistone A; Kota M; Passera C; Fiore S; Bino S; Amato C; Lozza A; Marseglia GL; Fiore L
BMC Infect Dis; 2016 Jun; 16():277. PubMed ID: 27287521
[TBL] [Abstract][Full Text] [Related]
18. Differences in Antigenic Structure of Inactivated Polio Vaccines Made From Sabin Live-Attenuated and Wild-Type Poliovirus Strains: Impact on Vaccine Potency Assays.
Crawt L; Atkinson E; Tedcastle A; Pegg E; ; Minor P; Cooper G; Rigsby P; Martin J
J Infect Dis; 2020 Feb; 221(4):544-552. PubMed ID: 30788503
[TBL] [Abstract][Full Text] [Related]
19. Rapid and accurate identification of poliovirus strains used for vaccine production.
Nijst OE; Mouthaan JJ; Mekkes DR; Jusic E; van der Avoort HG; Metz B
J Virol Methods; 2013 Apr; 189(1):189-95. PubMed ID: 23434540
[TBL] [Abstract][Full Text] [Related]
20. Sabin Vaccine Reversion in the Field: a Comprehensive Analysis of Sabin-Like Poliovirus Isolates in Nigeria.
Famulare M; Chang S; Iber J; Zhao K; Adeniji JA; Bukbuk D; Baba M; Behrend M; Burns CC; Oberste MS
J Virol; 2016 Jan; 90(1):317-31. PubMed ID: 26468545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
